refractory hairy cell leukemia

Dear Editor, Hairy cell leukemia (HCL) is a mature B-cell lymphoid cancer that can be treated successfully in the majority of… Expand

Purpose: To determine tolerability and for the first time explore efficacy of bendamustine–rituximab (BR) in multiply relapsed… Expand

In patients with advanced chemotherapy-refractory mesothelioma, treatment with the anti-mesothelin immunotoxin SS1P and… Expand

Dear Editor, Hairy-cell leukemia (HCL) is a rare hematological malignancy, which typically responds very well to first-line… Expand

The purine analogs, pentostatin and cladribine, induce high remission rates when used as first-line monotherapy for hairy cell… Expand

The purine analogs pentostatin and cladribine have revolutionized the treatment of hairy cell leukemia (HCL) with overall… Expand

An increasing number of patients who have hairy cell leukemia (HCL) have persistent disease that requires treatment, despite… Expand

The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or… Expand

We report major responses in 4 of 4 patients with hairy cell leukemia (HCL) who have recently been treated on a phase I trial… Expand

Our experience suggests a potential role of fludarabine phosphate in the management of hairy cell leukemia. On the basis of this… Expand